No information is available on the clinical use of ruxolitinib during breastfeeding. Because ruxolitinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ruxolitinib therapy and for 2 weeks after the last dose for the oral tablets and for 4 weeks after the last dose for the topical cream. However, ruxolitinib cream is approved for direct application in children as young as 2 years of age.
关于芦可替尼在母乳喂养期间的临床应用尚无可用信息。由于芦可替尼与血浆蛋白的结合率为97%，其在乳汁中的含量可能较低。制造商建议在芦可替尼治疗期间以及口服片剂最后一剂后2周内、局部乳膏最后一剂后4周内停止母乳喂养。
